Figure 4: AMLs with early epigenetic lesions have leukaemic and non-leukaemic repopulation capacities in NSG mice.
From: Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia
(a) Percentages of human CD45+ (hCD45+) cells in the bone marrow of NSG mice 8–43 weeks after injection of 5 × 106 mononuclear cells from 38 AML blood samples. The presence of candidate pre-leukaemic lesions in injected cells is indicated in the co-mutation table. (b) Flow cytometric analysis of NSG bone marrow repopulated with non-leukaemic (UPN2014-019, UPN2015-021) and leukaemic (UPN2014-043) cells. (c) Repopulation of NSG bone marrow by shRNA TET2 or scramble transduced cord blood CD34+ cells. Bars indicate the median (Mann–Whitney test). (d) Flow cytometric analysis of the bone marrow from two representative mice transplanted with control (shRNA scramble) and TET2 knocked-down (shRNA TET2) cells.
